Establishment and characterization of a panel of BRAFV600E colorectal XPDX models from patients with acquired resistance to targeted therapies. (October 2022) - Moriarty, A.; Flores, J.; Peskin, A.; Lynch, M.; Papadopoulos, K.; Lakhani, N.; Sharma, M.; Drengler, R.; Szender, J.; Rasco, D.; Patnaik, A.; Bucheit, A.; et al.